Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Afatinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ACCEPT
- 12 Feb 2021 Primary endpoint of Overall survival has not been met, according to results published in the European Journal of Cancer.
- 12 Feb 2021 Results published in the European Journal of Cancer
- 31 May 2020 Results estimating the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology